Systematic Review and Adjusted Indirect Comparison
Meta-Analyses of Oral Anticoagulants in
Atrial Fibrillation

William L. Baker, PharmD, BCPS; Olivia J. Phung, PharmD

Background—Oral anticoagulants such as apixaban, dabigatran, and rivaroxaban are alternatives to warfarin for preventing events in patients with atrial fibrillation. Direct comparative studies between agents are unavailable. Our objective was to conduct an adjusted indirect comparison meta-analysis between new oral agents in atrial fibrillation.

Methods and Results—We searched MEDLINE and Cochrane Central through February 2012 for randomized, controlled trials in patients with atrial fibrillation evaluating apixaban, dabigatran, or rivaroxaban versus warfarin. For dabigatran, only data from the Food and Drug Administration–approved dose were included. Outcomes included the composite of stroke or systemic embolism, any stroke, and major bleeding among, others. Outcomes were initially pooled using standard random-effects methods, producing risk ratio and 95% confidence intervals. Adjusted indirect comparisons using these pooled estimates were then performed. A total of 44,733 patients from 4 studies were analyzed. Most analyses yielded no differences between agents. Dabigatran lowered risk of composite outcome (risk ratio, 0.75; 95% confidence interval, 0.57–1.00), ischemic stroke (0.67; 0.48–0.93), and hemorrhagic stroke (0.45; 0.45–0.99) versus rivaroxaban. No differences in all strokes or mortality were seen. Apixaban lowered the risk of major bleeding (0.74; 0.60–0.91) and gastrointestinal bleeding (0.58; 0.41–0.82) versus dabigatran and major bleeding versus rivaroxaban (0.68; 0.55–0.83), but increased systemic emboli versus rivaroxaban (3.86; 1.17–12.75).

Conclusions—Significant differences in efficacy and safety parameters may exist between oral anticoagulant agents in patients with atrial fibrillation. Apixaban lowers the risk of major and gastrointestinal bleeding versus dabigatran and rivaroxaban. Dabigatran lowers the composite of stroke or systemic emboli, and ischemic stroke versus rivaroxaban. Head-to-head clinical trials are required to confirm these findings. (Circ Cardiovasc Qual Outcomes. 2012;5:711-719.)

Key Words: atrial fibrillation ■ ischemic stroke ■ warfarin ■ apixaban ■ dabigatran ■ rivaroxaban
WHAT IS KNOWN

• Direct comparative trials of newer oral anticoagulant agents are not available to help guide treatment choice.
• Adjusted indirect-comparison meta-analysis can be utilized to estimate efficacy and treatment differences when a common comparator is used.

WHAT THE STUDY ADDS

• Most analyses identified no difference between agents.
• Apixaban was associated with a lower risk of major and gastrointestinal bleeding versus dabigatran and rivaroxaban, whereas dabigatran was associated with a lower risk of the composite of stroke or systemic emboli and ischemic stroke versus rivaroxaban.
• Meta-regression analyses identified no confounding of effect when controlled for differences in CHADS2 score or time within the therapeutic international normalized ratio range.

Methods

The current review conforms to standard guidelines and was written according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement.10,11

Literature Search

We conducted a systematic literature using MEDLINE (beginning January 1950) and Cochrane Central through February 2012. The search strategy combined the Medical Subject Headings and keywords apixaban, dabigatran, rivaroxaban, oral Xa inhibitor, oral direct thrombin inhibitor combined with atrial fibrillation. The complete search strategy is shown in the in the online-only Data Supplement. No language restrictions were imposed. For the MEDLINE search, we used the Cochrane Collaboration’s Highly Sensitive Search Strategy sensitivity maximizing version for randomized, controlled trials (RCTs).11 A manual search of references from reports of clinical trials or review articles was performed to identify additional relevant studies. We also conducted a search of http://www.clinicaltrials.gov to identify relevant ongoing clinical studies of the same oral anticoagulants, or future ones.

Study Selection

Both investigators reviewed all potentially relevant articles in a parallel manner by using a priori defined criteria. Studies were eligible for inclusion in the systematic review if they were (1) a RCT in humans; (2) investigated patients with nonvalvular atrial fibrillation; (3) evaluated apixaban, dabigatran, or rivaroxaban, oral Xa inhibitor, oral direct thrombin inhibitor combined with atrial fibrillation. The complete search strategy is shown in the in the online-only Data Supplement. No language restrictions were imposed. For the MEDLINE search, we used the Cochrane Collaboration’s Highly Sensitive Search Strategy sensitivity maximizing version for randomized, controlled trials (RCTs).11 A manual search of references from reports of clinical trials or review articles was performed to identify additional relevant studies. We also conducted a search of http://www.clinicaltrials.gov to identify relevant ongoing clinical studies of the same oral anticoagulants, or future ones.

Data Abstraction

For each included study, both investigators used a standardized data abstraction tool to independently extract all data, with disagreements resolved by discussion. The following information was sought from each trial: author, year, study design, duration of follow-up, population and setting, time spent within therapeutic international normalized ratio range (TTR), and clinical outcomes. Efficacy outcomes included the composite of stroke or systemic emboli, any stroke, ischemic stroke, systemic emboli, and mortality. Safety outcomes included major bleeding, hemorrhagic stroke, and gastrointestinal bleeding. Only data from the intention-to-treat analysis of each study was included in this analysis. If the United States Food and Drug Administration approved 1 of the drugs for prevention of stroke in atrial fibrillation, only data from the Food and Drug Administration-approved dose for this indication were extracted.

Validity Assessment

Following the Methods Guide for Comparative Effectiveness Reviews, both reviewers assessed the quality of each study by answering yes, no, or unclear to 11 questions regarding similarity of baseline populations, randomization, allocation concealment, blinding of study participants and personnel, outcome adjudication, completeness of follow-up, and conflicts of interest.12 Studies were given an overall score of good, fair, or poor with disagreements resolved through discussion. We also used methods from the Agency for Healthcare Research and Quality Evidence-Based Practice Centers for grading the strength of evidence (SOE) for each of the main outcomes based on Grading of Recommendations Assessment, Development, and Evaluation.13 Evidence quality was rated as high (further research is very unlikely to change the confidence in the estimate of effect, meaning that the evidence reflects the true effect), moderate, low, or insufficient (evidence is unavailable or does not permit a conclusion). Domains evaluated to rate the SOE included (1) risk for bias, (2) consistency, (3) directness, and (4) precision. Grading for each outcome can be found in online-only Data Supplement Tables I to IV.

Statistical Analysis

Traditional pair-wise meta-analysis was first conducted with events analyzed as categorical variables. Analyses were conducted for each pair-wise comparison separately. Weighted averages were reported as risk ratio (RR) with associated confidence intervals (CIs) using a DerSimonian and Laird random-effects model.14 Statistical significance will be stated using a threshold P value of 0.01 (with corresponding 99% CI provided) given the number of comparisons conducted and small number of studies included. To better evaluate the magnitude of potential differences between agents, absolute risk differences and number needed to treat with associated 95% CI were calculated. Traditional meta-analysis statistics were performed using Comprehensive Meta-Analysis, Version 2 (Biostat, Englewood, NJ). Adjusted indirect comparisons of pooled estimates using inverse variance weighting were then performed according to the methods of Bucher and colleagues using the indirect treatment comparison computer program, Version 1.0.6,15 The likelihood of statistical heterogeneity was assessed using the I² statistic (an I² >25% is considered representative of important statistical heterogeneity).16 We evaluated the presence of publication bias and related biases by using funnel plots and Egger tests, but the small number of studies limited the ability of these methods to detect publication bias.17

One of the underlying assumptions of adjusted indirect comparison meta-analyses is that the included trials are similar. This includes both methodological as well as patient characteristics. Two patient characteristics that are influential to the rate of both efficacy and safety events in this population is the stroke risk, measured by mean CHADS2 score, and the quality of warfarin management, measured by TTR. To assess whether differences in these 2 variables affected outcomes, random-effects meta-regression analyses were conducted. Meta-regression analyses were performed using Comprehensive Meta-Analysis, Version 2 (Biostat, Englewood, NJ).
Results

Study Selection and Characteristics

The results of our literature search are shown in Figure 1. In brief, after initially screening 237 citations and 26 full-text articles, a total of 4 unique RCTs met our inclusion criteria and were included in the quantitative analysis (Table 1).4-6,18 A total of 11 citations, primarily representing subgroup analyses of the 4 main RCTs, were included in the qualitative analysis.19-29

Of the RCTs, 2 evaluated dabigatran,4,18 whereas 1 each evaluated rivaroxaban and apixaban.6 Each of the studies enrolled patients with nonvalvular atrial fibrillation. The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial compared dabigatran versus warfarin in 18,113 patients using a prospective, randomized, open-label, blinded end-point evaluation design, with a median follow-up period of 2 years.4 Only data from the dabigatran 150 mg arm of RE-LY was included in this analysis, because this was the Food and Drug Administration-approved dose for this indication. Patients in RE-LY had a mean CHADS2 score of 2.1, with around one third of patients having a score ≥3. In the warfarin dosing arm, patients had a mean TTR of 64% with approximately half of the patients being naïve to warfarin prior to study enrollment. The Prevention of Embolic and Thrombotic Events in Patients with Persistent Atrial Fibrillation (PETRO) study18 was unique from RE-LY4 in that it was a dose-ranging study of 502 patients comparing dabigatran either with or without aspirin versus adjusted-dose warfarin. We only included data from the dabigatran 150 mg (without aspirin) arm in this analysis. The mean CHADS2 score was not reported and the mean TTR was 57.2%. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation (ROCKET-AF) was a randomized, double-blind trial of 14,264 patients with nonvalvular atrial fibrillation with a mean duration of follow-up of 1.94 years.7 Patients had a mean CHADS2 score of 3.5 and patients in the warfarin arm had a mean TTR of 55%. The last included study was the Apixaban versus Warfarin in Patients with Atrial Fibrillation (ARISTOTLE) study.6 This randomized, double-blind study included 18,201 patients with nonvalvular atrial fibrillation with a mean duration of follow-up of 1.8 years. Patients had a mean CHADS2 score of 2.1 and patients in the warfarin arm had a mean TTR of 62.2%.

New Agents Versus Warfarin

The comparative effects of newer oral anticoagulants versus warfarin on outcomes of interest are shown in Figure 2. In general, the composite of stroke or systemic emboli (RR, 0.80; 95% CI, 0.70–0.91; SOE moderate) and any stroke (RR, 0.77; 95% CI, 0.64–0.92; SOE high) were significantly reduced with the newer agents compared with warfarin. Similarly, all-cause mortality (RR, 0.87; 95% CI, 0.80–0.97; SOE high) and hemorrhagic stroke (RR, 0.46; 95% CI, 0.27–0.77; SOE low) were also significantly lower with the newer agents. No significant differences were seen for any other outcomes. Significant statistical heterogeneity was seen in a few analyses including any stroke ($I^2=28.5\%$), major bleed ($I^2=80.6\%$),...
hemorrhagic stroke ($I^2=52.1\%$), and gastrointestinal bleed ($I^2=82.5\%$).

**Apixaban Versus Dabigatran**

Results of the adjusted indirect comparison between apixaban and dabigatran can be found in Figure 3A. Efficacy outcomes, including the composite of stroke or systemic emboli (RR, 1.19; 95% CI, 0.90–1.58; SOE moderate), ischemic stroke (RR, 1.19; 95% CI, 0.86–1.65; SOE moderate), any stroke (RR, 1.21; 95% CI, 0.91–1.62; SOE moderate), and mortality (RR, 1.01; 95% CI, 0.86–1.19; SOE moderate) did not differ between the agents. Apixaban was associated with a lower risk of major bleeding (RR, 0.75; 95% CI, 0.62–0.92; SOE moderate) and gastrointestinal bleeding (RR, 0.60; 95% CI, 0.43–0.84; SOE moderate), whereas a trend toward a significant increase in hemorrhagic stroke (RR, 1.93; 95% CI, 0.93–4.02; SOE low) was seen compared with dabigatran. Sufficient data were not available to conduct an indirect comparison for systemic emboli.

**Dabigatran Versus Rivaroxaban**

Results of the adjusted indirect comparison between dabigatran and rivaroxaban can be found in Figure 3B. Dabigatran was associated with a significantly lower risk of the composite of stroke or systemic emboli (RR, 0.76; 95% CI, 0.58–0.99; SOE moderate) and ischemic stroke (RR, 0.68; 95% CI, 0.49–0.93;
Figure 2. Forest plots comparing newer agents vs warfarin. A, Composite of stroke or systemic embolism; B, ischemic stroke; C, systemic emboli; D, any stroke; E, mortality; F, major bleed; G, hemorrhagic stroke; H, gastrointestinal bleed. RE-LY indicates Randomized Evaluation of Long-Term Anticoagulation Therapy; ROCKET-AF, Rivaroxaban vs Warfarin in Nonvalvular Atrial Fibrillation; ARISTOTLE, Apixaban vs Warfarin in Patients with Atrial Fibrillation; CI, confidence interval; and NA, not available.
SOE moderate) versus rivaroxaban, whereas no difference in any stroke (RR, 0.78; 95% CI, 0.58–1.05; SOE moderate) or mortality (RR, 1.07; 95% CI, 0.86–1.33; SOE moderate) was seen. No significant difference in either major bleeding (RR, 0.91; 95% CI, 0.75–1.11; SOE moderate) or gastrointestinal bleeding (RR, 0.97; 95% CI, 0.72–1.31; SOE moderate) was seen between the agents, whereas dabigatran significantly reduced the risk of hemorrhagic stroke (RR, 0.45; 95% CI, 0.21–0.98; SOE moderate) compared with rivaroxaban. Sufficient data were not available to conduct indirect comparisons for either systemic emboli or gastrointestinal bleeding.

### Apixaban Versus Rivaroxaban

Results of the adjusted indirect comparison between apixaban and rivaroxaban can be found in Figure 3C. No significant differences in the composite of stroke of systemic emboli (RR, 0.91; 95% CI, 0.71–1.15; SOE moderate), ischemic stroke (RR, 0.80; 95% CI, 0.60–1.08; SOE moderate), any stroke (RR, 0.95; 95% CI, 0.73–1.24; SOE moderate), or mortality (RR, 1.08; 95% CI, 0.87–1.33; SOE moderate) was seen between the agents, although apixaban was associated with an increased risk of systemic emboli (RR, 3.85; 95% CI, 1.20–12.36; SOE low) versus rivaroxaban. Apixaban decreased the risk of major bleeding (RR, 0.69; 95% CI, 0.57–0.84; SOE moderate) versus rivaroxaban, although no difference in hemorrhagic stroke (RR, 0.88; 95% CI, 0.49–1.58; SOE low) was seen. Sufficient data were not available to conduct an indirect comparison for gastrointestinal bleeding.

### Absolute Risk Difference

To put the potential differences in outcomes between agents into clinical context, we calculated the absolute difference in events per 1000 patients treated (Table 2). As compared with warfarin, the newer agents resulted in 7 fewer composite...
Table 2. Absolute Differences in Events per 1000 Patients Treated

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Agents vs Warfarin</th>
<th>Apixaban vs Dabigatran</th>
<th>Dabigatran vs Rivaroxaban</th>
<th>Apixaban vs Rivaroxaban</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stroke or systemic emboli</td>
<td>−7 (−11 to −3)</td>
<td>−5 (−12 to 3)</td>
<td>−6 (−14 to 3)</td>
<td>−1 (−9 to 7)</td>
</tr>
<tr>
<td>Ischemic stroke</td>
<td>−3 (−6 to 1)</td>
<td>4 (−3 to 10)</td>
<td>−9 (−16 to −1)</td>
<td>−5 (−11 to 2)</td>
</tr>
<tr>
<td>Systemic emboli</td>
<td>0 (−2 to 1)</td>
<td>NA</td>
<td>NA</td>
<td>2 (0 to 4)</td>
</tr>
<tr>
<td>Any stroke</td>
<td>−7 (−11 to −3)</td>
<td>5 (−2 to 12)</td>
<td>−5 (−13 to 2)</td>
<td>−1 (−8 to 7)</td>
</tr>
<tr>
<td>Mortality</td>
<td>−7 (−12 to −2)</td>
<td>1 (−11 to 13)</td>
<td>−3 (−14 to 8)</td>
<td>−2 (−11 to 8)</td>
</tr>
<tr>
<td>Major bleed</td>
<td>−6 (−18 to −6)</td>
<td>−11 (−21 to 0)</td>
<td>−6 (−14 to 3)</td>
<td>−16 (−26 to −7)</td>
</tr>
<tr>
<td>Hemorrhagic stroke</td>
<td>−4 (−6 to −2)</td>
<td>1 (−2 to 5)</td>
<td>−3 (−6 to 1)</td>
<td>−1 (−5 to 2)</td>
</tr>
<tr>
<td>Gastrointestinal bleed</td>
<td>6 (−5 to 17)</td>
<td>−12 (−18 to −5)</td>
<td>0 (−8 to 8)</td>
<td>−11 (−18 to −5)</td>
</tr>
</tbody>
</table>

NA indicates not available.
Data are presented as risk difference (95% confidence interval).

(stroke or systemic emboli) events, 7 fewer strokes, 7 fewer deaths, and 4 fewer hemorrhagic strokes per 1000 patients treated. Apixaban resulted in 12 fewer gastrointestinal bleeds than dabigatran and 11 fewer than rivaroxaban, as well as 16 fewer major bleeds than rivaroxaban. Dabigatran resulted in 9 fewer ischemic strokes than rivaroxaban.

Meta-Regression

Random-effects meta-regression was run for each of the efficacy and safety outcomes controlling for differences in mean CHADS\textsubscript{2} score and TTR. Sufficient data were not available to conduct meta-regression on systemic emboli. No significant association was found between either CHADS\textsubscript{2} score or TTR and any of the efficacy or safety outcomes (online-only Data Supplement Figure 1A through 1E).

Ongoing Research

We identified phase III clinical trials for other new oral anticoagulants for preventing stroke in patients with atrial fibrillation. Edoxaban, an oral factor Xa inhibitor, is being compared with dose-adjusted warfarin in the Effective Anticoagulation With Xa Next Generation in Atrial Fibrillation - Thrombolysis in Myocardial Infarction Study 48 (ENGAGE AF-TIMI 48) trial, which is still ongoing (NCT00781391). Although a number of other agents have been evaluated in phase I and II trials, no other agents have active phase III trials ongoing in this area.

Comment

This meta-analysis of >44000 patients from 4 clinical trials found that, compared with dose-adjusted warfarin, newer oral anticoagulants resulted in significant reductions in stroke or systemic embolism, all strokes, mortality, and hemorrhagic stroke with similar rates of ischemic stroke, hemorrhagic stroke, major bleed, and gastrointestinal bleed. When the newer oral agents were indirectly compared, a few potential differences were seen. As compared with rivaroxaban, dabigatran was associated with lower risk of stroke or systemic embolism, ischemic stroke, and hemorrhagic stroke, whereas apixaban was associated with lower risk of major and gastrointestinal bleeds and higher risk of systemic emboli. As compared with dabigatran, apixaban was associated with lower risk of major and gastrointestinal bleeds. With the lack of available head-to-head studies, these data provide the first indirect comparisons between these newer oral anticoagulant agents in patients with nonvalvular atrial fibrillation.

One of the main criticisms with undertaking such adjusted indirect comparison relates to differences in pertinent factors between the clinical trials, most specifically the CHADS\textsubscript{2} score and TTR on warfarin.\textsuperscript{31} These 2 factors related to the baseline stroke risk in the trial populations (CHADS\textsubscript{2}) and the adequacy of the warfarin control (TTR). The ROCKET-AF study\textsuperscript{3} included patients at a higher stroke risk (mean CHADS\textsubscript{2}=3.5) compared with RE-LY\textsuperscript{4} (mean CHADS\textsubscript{2}=2.1) and ARISTOTLE (mean CHADS\textsubscript{2}=2.1).\textsuperscript{5} Patients in the adjusted-dose warfarin arm also had poorer international normalized ratio control, as reflected by a mean TTR of 55% compared with 64% in RE-LY and 62.2% in ARISTOTLE. In an attempt to quantify the association between CHADS\textsubscript{2} score and TTR in these studies, we conducted meta-regression analyses. These results showed no association between these factors and any of the efficacy or safety outcomes of interest. This suggests that, although nominal differences in these factors exist between the studies, they may not significantly modify the treatment effect seen when comparing the newer oral anticoagulants to warfarin.

Our findings are supported by the results of a subgroup analysis of the RE-LY trial,\textsuperscript{32} which showed that although risk of clinical events was higher with increasing CHADS\textsubscript{2} scores, the benefits of dabigatran compared with warfarin were seen across all CHADS\textsubscript{2} score strata.

Two prior indirect comparison meta-analyses have been published evaluating pharmacological strategies to prevent stroke in atrial fibrillation.\textsuperscript{32,33} Roskell et al\textsuperscript{3} conducted indirect comparisons and network meta-analyses of all pharmacological agents as compared with dabigatran. They suggested that dabigatran reduced stroke, systemic embolism, and mortality versus warfarin as well as antiplatelet agents and placebo. Their results are supported by a recently published study that showed apixaban to be superior to aspirin in reducing the risk of stroke or systemic embolism without affecting risk of major bleeding or intracranial hemorrhage in patients unsuitable for warfarin.\textsuperscript{34} Our study differed from theirs in that we limited the analyses to only the newer oral anticoagulants as compared with warfarin and included 2 newer agents, rivaroxaban and apixaban, data for which were not available for the prior meta-analyses. In addition, given the small number of studies included in our analysis, we did not feel that a network meta-analysis performed using a Bayesian framework...
would yield reliable results. Thus, we chose a more conservative approach using adjusted indirect comparison methods.

One of the biggest questions facing clinical practitioners caring for patients with atrial fibrillation at risk for stroke is which oral anticoagulant should be initiated? A number of factors have to be taken into consideration, including the effectiveness, convenience of administration, cost, ease of reversal, and adverse events. Dabigatran and apixaban are each taken twice daily, whereas rivaroxaban can be taken once daily. A number of studies have demonstrated dabigatran and rivaroxaban to be cost-effective strategies for preventing stroke in atrial fibrillation. A common concern with these new oral agents is the ability to reverse their anticoagulant properties in emergency situations. A study by Eerenberg et al. showed that use of prothrombin complex concentrate reversed the activity of rivaroxaban, but not dabigatran in a small study of healthy volunteers. These factors, in addition to the potential differences in efficacy and safety seen in our study, have to be taken into account when deciding on the most appropriate agent for a specific patient. Additional studies are required to better elucidate the situations under which each specific agent is appropriate for use in place of warfarin.

Adjusted indirect comparison meta-analysis is an established statistical technique that can provide useful information in the absence of sufficient head-to-head evidence. Some have argued that adjusted indirect comparisons produce less bias than direct comparative studies, although this hypothesis requires further research. A concern with using this method to indirectly compare the efficacy and safety of oral anticoagulant agents in atrial fibrillation is variation in the patient populations of the included studies. A task force on indirect treatment comparisons parisons good research practices, formed by the International Society of Pharmacoeconomic and Outcomes Research, stated that a degree of relative variation in the patient populations is welcome for comparative evaluations, as they may more adequately reflect real-world clinical situations. Specific to stroke prevention in atrial fibrillation, the baseline stroke risk of the population (CHADS2 score) and the adequacy of warfarin control (TTR) are of importance. When we conducted meta-regression analyses to control for these variables, no significant association was found with any of the efficacy or safety variables. This further strengthens the assumptions that underlie our adjusted indirect comparison analyses. However, given the small number of studies included in the meta-regression, the results are likely underpowered and should be interpreted accordingly. Moreover, results from our study should be viewed as hypothesis generating, and should be confirmed with head-to-head comparisons. Another limitation to this analysis is the potential for statistical, as well as clinical and methodological, heterogeneity between studies. Our analysis showed significant statistical heterogeneity in a few analyses, which may be the result of differences in the individual agents on outcome risk.

Conclusions
Significant differences in pertinent efficacy and safety parameters may exist between oral anticoagulant agents in patients with nonvalvular atrial fibrillation. Apixaban lowers the risk of major and gastrointestinal bleeding versus dabigatran and rivaroxaban. Dabigatran lowers the composite stroke or systemic emboli, and ischemic stroke versus rivaroxaban. Although direct head-to-head clinical trials are required to confirm the findings of this adjusted indirect comparison analysis, they are unlikely to be conducted. Data from real-world patient registries may shed light on differences between these agents.

Disclosures
None.

References
research and quality and the effective health-care program. *J Clin Epide-

als.* 1986;7:177–188.

15. Wells GA, Sutlran SA, Chen L, Khan M, Coyle D. Indirect treatment com-
parison [computer program]. Version 1.0. Ottawa: Canadian Agency for
Drugs and Technologies in Health; 2009.

16. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsis-

17. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis

alone in patients with nonvalvular atrial fibrillation (PETRO Study). *Am J
Cardiol.* 2007;100:1419–1426.

19. Diener HC, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, Yang S,

20. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Old-

mittee and Investigators. Dabigatran and warfarin in vitamin K antago-
* 2010;122:2246–2253.


RE-LY Investigators. Efficacy and safety of dabigatran vs. warfarin in
patients with atrial fibrillation–sub-analysis in Japanese population in


events in patients with atrial fibrillation treated with dabigatran or warfa-
rin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation


30. Ruff CT, Giugliano RP, Antman EM, Cugnale SE, Bocanegra T, Mercuri M, Hanyok J, Patel J, Shi M, Salazar D, McCabe CH, Braunwald E. Eval-

31. Katnelson M, Socco RL, Moscussi M. Progress for stroke prevention with
atrial fibrillation. Emergence of alternative oral anticoagulants. *Circula-

32. Cooper NJ, Sutton AJ, Liu G, Khunti K. Mixed comparison of stroke pre-

33. Roskell NS, Lip GY, Noack H, Clemens A, Plumb JM. Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and in-
direct comparisons versus dabigatran etexilate. *Thromb Haemost.* 2010;
104:1106–1115.

rence J, Lewis G, Afsal R, Yusuf S; AVERROES Steering Committee and


36. Sorensen SV, Kansal AR, Connolly S, Peng S, Linnehan J, Bradley-
Kennedy C, Plumb JM. Cost-effectiveness of dabigatran etexilate for

37. Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis


39. Eerenberg BS, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex
concentrate: a randomized, placebo-controlled, crossover study in healthy

40. Song F, Harvey I, Lilford R. Adjusted indirect comparison may be less
biased than direct comparison for evaluating new pharmaceutical inter-


comparisons and network meta-analysis for health-care decision making:
report of the ISPOR Task Force on Indirect Treatment Comparisons Good
Systematic Review and Adjusted Indirect Comparison Meta-Analysis of Oral Anticoagulants in Atrial Fibrillation
William L. Baker and Olivia J. Phung

Circ Cardiovasc Qual Outcomes. 2012;5:711-719; originally published online August 21, 2012; doi: 10.1161/CIRCOUTCOMES.112.966572
Circulation: Cardiovascular Quality and Outcomes is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2012 American Heart Association, Inc. All rights reserved.
Print ISSN: 1941-7705. Online ISSN: 1941-7713

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circoutcomes.ahajournals.org/content/5/5/711

Data Supplement (unedited) at:
http://circoutcomes.ahajournals.org/content/suppl/2012/08/21/CIRCOUTCOMES.112.966572.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation: Cardiovascular Quality and Outcomes can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation: Cardiovascular Quality and Outcomes is online at:
http://circoutcomes.ahajournals.org//subscriptions/
SUPPLEMENTAL MATERIAL

Appendix 1. Search Strategy

1. apixaban.mp.
2. BMS-562247.mp.
3. dabigatran.mp.
4. bay 59-7939.mp.
5. rivaroxaban.mp.
6. BIBR 1048.mp.
7. oral xa inhibitor.mp.
8. oral direct thrombin inhibitor.mp.
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10. Atrial Fibrillation/
11. afib.mp.
12. 10 or 11
13. 9 and 12
**eTable 1. Quality of Evidence for Newer Anticoagulants versus Warfarin**

<table>
<thead>
<tr>
<th>Quality assessment</th>
<th>Summary of findings</th>
<th>No of patients</th>
<th>Effect</th>
<th>Quality</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No of patients</td>
<td>Experimental</td>
<td>Control</td>
<td>Relative (95% CI)</td>
<td>Absolute (95% CI)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stroke or Systemic Emboli</td>
<td>4 RCTs</td>
<td>No serious limitations</td>
<td>No serious inconsistency</td>
<td>No serious indirectness</td>
<td>No serious imprecision</td>
</tr>
<tr>
<td>Ischemic Stroke</td>
<td>3 RCTs</td>
<td>No serious limitations</td>
<td>No serious inconsistency</td>
<td>No serious indirectness</td>
<td>No serious imprecision</td>
</tr>
<tr>
<td>Systemic Emboli</td>
<td>2 RCTs</td>
<td>No serious limitations</td>
<td>No serious inconsistency</td>
<td>No serious indirectness</td>
<td>No serious imprecision</td>
</tr>
<tr>
<td>Any Stroke</td>
<td>3 RCTs</td>
<td>No serious limitations</td>
<td>No serious inconsistency</td>
<td>No serious indirectness</td>
<td>No serious imprecision</td>
</tr>
<tr>
<td>Mortality</td>
<td>3 RCTs</td>
<td>No serious limitations</td>
<td>No serious inconsistency</td>
<td>No serious indirectness</td>
<td>No serious imprecision</td>
</tr>
<tr>
<td>Major Bleed</td>
<td>4 RCTs</td>
<td>No serious limitations</td>
<td>Serious inconsistency</td>
<td>No serious indirectness</td>
<td>No serious imprecision</td>
</tr>
<tr>
<td>Hemorrhagic Stroke</td>
<td>3 RCTs</td>
<td>No serious limitations</td>
<td>Serious inconsistency</td>
<td>No serious indirectness</td>
<td>Serious imprecision</td>
</tr>
<tr>
<td>Gastrointestinal Bleed</td>
<td>3 RCTs</td>
<td>No serious limitations</td>
<td>Serious inconsistency</td>
<td>No serious indirectness</td>
<td>Serious imprecision</td>
</tr>
</tbody>
</table>

Footnotes: ¹ Lack of or inadequate information about blinding
## eTable 2. Quality of Evidence for Apixaban versus Dabigatran

<table>
<thead>
<tr>
<th>Quality assessment</th>
<th>Summary of findings</th>
<th>Quality</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>No of patients</td>
<td>Effect</td>
<td>Relative (95% CI)</td>
<td>Absolute (95% CI)</td>
</tr>
<tr>
<td>Experimental</td>
<td>Control</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Stroke or Systemic Emboli

| 3 RCTs | No serious limitations | NA | Serious indirectness | No serious imprecision | None | 615/22377 (2.7%) | 770/22,263 (3.5%) | 1.19 (0.90-1.58) | -5 (-12 to 3) | MODERATE | CRITICAL |

### Ischemic Stroke

| 2 RCTs | No serious limitations | NA | Serious indirectness | No serious imprecision | None | 422/22257 (9%) | 478/22185 (9%) | 1.19 (0.86-1.65) | 4 (-3 to 10) | MODERATE | CRITICAL |

### Any Stroke

| 2 RCTs | No serious limitations | NA | Serious indirectness | No serious imprecision | None | 20/16181 (8.1%) | 39/16163 (9%) | 1.21 (0.91-1.62) | 5 (-2 to 12) | MODERATE | CRITICAL |

### Mortality

| 2 RCTs | No serious limitations | NA | Serious indirectness | No serious imprecision | None | 505/22257 (8.1%) | 656/22185 (9%) | 1.01 (0.86-1.19) | 1 (-11 to 13) | MODERATE | CRITICAL |

### Major Bleed

| 3 RCTs | No serious limitations | NA | Serious indirectness | No serious imprecision | None | 1552/19077 (8.1%) | 1714/19059 (9%) | 0.75 (0.62-0.92) | -11 (-21 to 0) | MODERATE | CRITICAL |

### Hemorrhagic Stroke

| 2 RCTs | No serious limitations | NA | Serious indirectness | Serious imprecision | None | 1552/19077 (8.1%) | 1714/19059 (9%) | 1.93 (0.93-4.02) | 1 (-2 to 5) | LOW | CRITICAL |

### Gastrointestinal Bleed

| 2 RCTs | No serious limitations | NA | Serious indirectness | No serious imprecision | None | 1552/19077 (8.1%) | 1714/19059 (9%) | 0.60 (0.43-0.84) | -12 (-18 to -5) | MODERATE | IMPORTANT |

**Footnotes:** ¹ Number of studies included in the indirect comparison. None were available for direct comparisons.
### eTable 3. Quality of Evidence for Dabigatran versus Rivaroxaban

<table>
<thead>
<tr>
<th>Quality assessment</th>
<th>Summary of findings</th>
<th>Quality</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No of patients</td>
<td>Effect</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Experimental</td>
<td>Control</td>
<td>Relative (95% CI)</td>
</tr>
</tbody>
</table>

#### Stroke or Systemic Emboli

<table>
<thead>
<tr>
<th>No of studies</th>
<th>Design Limitations</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other considerations</th>
<th>No of patients</th>
<th>Effect</th>
<th>Quality</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 RCTs</td>
<td>No serious limitations</td>
<td>NA</td>
<td>Serious indirectness</td>
<td>No serious imprecision</td>
<td>None</td>
<td>615/22377 (2.7%)</td>
<td>770/22,263 (3.5%)</td>
<td>0.76 (0.58-0.99)</td>
</tr>
</tbody>
</table>

#### Ischemic Stroke

<table>
<thead>
<tr>
<th>No of studies</th>
<th>Design Limitations</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other considerations</th>
<th>No of patients</th>
<th>Effect</th>
<th>Quality</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 RCTs</td>
<td>No serious limitations</td>
<td>NA</td>
<td>Serious indirectness</td>
<td>No serious imprecision</td>
<td>None</td>
<td>422/22257 (9%)</td>
<td>478/22185 (9%)</td>
<td>0.68 (0.49-0.93)</td>
</tr>
</tbody>
</table>

#### Any Stroke

<table>
<thead>
<tr>
<th>No of studies</th>
<th>Design Limitations</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other considerations</th>
<th>No of patients</th>
<th>Effect</th>
<th>Quality</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 RCTs</td>
<td>No serious limitations</td>
<td>NA</td>
<td>Serious indirectness</td>
<td>No serious imprecision</td>
<td>None</td>
<td>20/16181 (8.1%)</td>
<td>39/16163 (9%)</td>
<td>0.78 (0.58-1.05)</td>
</tr>
</tbody>
</table>

#### Mortality

<table>
<thead>
<tr>
<th>No of studies</th>
<th>Design Limitations</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other considerations</th>
<th>No of patients</th>
<th>Effect</th>
<th>Quality</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 RCTs</td>
<td>No serious limitations</td>
<td>NA</td>
<td>Serious indirectness</td>
<td>No serious imprecision</td>
<td>None</td>
<td>505/22257 (8.1%)</td>
<td>656/22185 (9%)</td>
<td>1.07 (0.86-1.33)</td>
</tr>
</tbody>
</table>

#### Major Bleed

<table>
<thead>
<tr>
<th>No of studies</th>
<th>Design Limitations</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other considerations</th>
<th>No of patients</th>
<th>Effect</th>
<th>Quality</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 RCTs</td>
<td>No serious limitations</td>
<td>NA</td>
<td>Serious indirectness</td>
<td>No serious imprecision</td>
<td>None</td>
<td>1552/19077 (8.1%)</td>
<td>1714/19059 (9%)</td>
<td>0.91 (0.75-1.11)</td>
</tr>
</tbody>
</table>

#### Hemorrhagic Stroke

<table>
<thead>
<tr>
<th>No of studies</th>
<th>Design Limitations</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other considerations</th>
<th>No of patients</th>
<th>Effect</th>
<th>Quality</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 RCTs</td>
<td>No serious limitations</td>
<td>NA</td>
<td>Serious indirectness</td>
<td>No serious imprecision</td>
<td>None</td>
<td>1552/19077 (8.1%)</td>
<td>1714/19059 (9%)</td>
<td>0.45 (0.21-0.98)</td>
</tr>
</tbody>
</table>

#### Gastrointestinal Bleed

<table>
<thead>
<tr>
<th>No of studies</th>
<th>Design Limitations</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Other considerations</th>
<th>No of patients</th>
<th>Effect</th>
<th>Quality</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 RCTs</td>
<td>No serious limitations</td>
<td>NA</td>
<td>Serious indirectness</td>
<td>No serious imprecision</td>
<td>None</td>
<td>1552/19077 (8.1%)</td>
<td>1714/19059 (9%)</td>
<td>0.97 (0.72-1.31)</td>
</tr>
</tbody>
</table>

**Footnotes:** 1 Number of studies included in the indirect comparison. None were available for direct comparisons.
## eTable 4. Quality of Evidence for Apixaban versus Rivaroxaban

<table>
<thead>
<tr>
<th>Quality assessment</th>
<th>Summary of findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>No of studies&lt;sup&gt;1&lt;/sup&gt;</td>
<td>Design</td>
</tr>
<tr>
<td>Stroke or Systemic Emboli</td>
<td>2</td>
</tr>
<tr>
<td>Ischemic Stroke</td>
<td>2</td>
</tr>
<tr>
<td>Systemic Emboli</td>
<td>2</td>
</tr>
<tr>
<td>Any Stroke</td>
<td>2</td>
</tr>
<tr>
<td>Mortality</td>
<td>2</td>
</tr>
<tr>
<td>Major Bleed</td>
<td>2</td>
</tr>
<tr>
<td>Hemorrhagic Stroke</td>
<td>2</td>
</tr>
<tr>
<td>Gastrointestinal Bleed</td>
<td>2</td>
</tr>
</tbody>
</table>

**Footnotes:**<sup>1</sup> Number of studies included in the indirect comparison. None were available for direct comparisons.
Figure 1. Results of Meta-Regression Analyses

A. Composite of Stroke or Systemic Embolism

Regression of TTR on Log risk ratio

Regression of CHADS2 Score on Log risk ratio

\( p = 0.13 \)

\( p = 0.27 \)
B. Ischemic Stroke

Regression of TTR on Log risk ratio

Regression of CHADS2 Score on Log risk ratio
C. Any Stroke

Regression of TTR on Log risk ratio

Regression of CHADS2 Score on Log risk ratio

\[ p = 0.30 \]

\[ p = 0.42 \]
D. Mortality

Regression of TTR on Log risk ratio

\[ \text{Log risk ratio} \]

TTR

\[ p = 0.78 \]

Regression of CHADS2 Score on Log risk ratio

\[ \text{Log risk ratio} \]

CHADS2 Score

\[ p = 0.78 \]
E. Major Bleeding

**Regression of TTR on Log risk ratio**

- Log risk ratio
- TTR
- $p = 0.67$

**Regression of CHADS2 Score on Log risk ratio**

- Log risk ratio
- CHADS2 Score
- $p = 0.39$
E. Hemorrhagic Stroke

Regression of TTR on Log risk ratio

Regression of CHADS2 Score on Log risk ratio

p = 0.35

p = 0.46
E. Gastrointestinal Bleed

Regression of TTR on Log risk ratio

Regression of CHADS2 Score on Log risk ratio

\[ p = 0.58 \]

\[ p = 0.53 \]